18 studies found for:    "Splenomegaly"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly
Conditions: Hyper-reactive Malarial Splenomegaly;   Malaria;   Anaemia
Interventions: Drug: prednisone induction - chloroquine;   Drug: Chloroquine
2 Completed Spleen Size in Peripheral Blood Stem Cell Donors
Condition: Splenomegaly
Intervention:
3 Enrolling by invitation Estimation of Spleen by Residents With VScan
Condition: Splenomegaly
Intervention: Device: VScan Ultrasound (GE Healthcare, USA)
4 Completed Ultrasound Estimation of Spleen Size
Condition: Splenomegaly
Interventions: Device: Vscan Ultrasound (GE Healthcare, USA);   Device: Conventional Ultrasound
5 Completed Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination
Conditions: Splenomegaly;   Pleural Effusion
Intervention: Device: resident with GE vscan
6 Unknown  Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
Conditions: Liver Cirrhosis;   Carcinoma, Hepatocellular;   Splenomegaly;   Laparotomy
Intervention:
7 Completed Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
Condition: Myelofibrosis
Intervention: Drug: SAR302503
8 Completed Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503;   Drug: Placebo
9 Completed Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
10 Completed Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease;   Lymphoproliferative Disorder
Intervention: Drug: Fansidar (pyrimethamine and sulfadoxine)
11 Active, not recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
12 Completed Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder
Intervention: Drug: Pyrimethamine
13 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
14 Completed
Has Results
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: ALPS;   Hypersplenism;   Lymphadenopathy
Interventions: Drug: Valproic Acid;   Procedure: CT Scan;   Procedure: Blood Sample
15 Completed Prospective Randomized Comparison of Clinical Results of Hand Assisted Laparoscopic Splenectomies and Open Splenectomies
Condition: Postoperative Pain
Intervention:
16 No longer available Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
17 Unknown  Hemolysis in Patients With Hereditary Spherocytosis (HS)
Conditions: Hereditary;   Hemolysis
Intervention: Other: fermented papaya preparation (FPP)
18 Recruiting Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Condition: Thalassemia Major
Intervention: Drug: INC424 (ruxolitinib)

Indicates status has not been verified in more than two years